Anthony Uribes, MD
Family Medicine · Wauseon, OHNPI 1720084791
Payments from drug & device makers
Across 446 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$930
- AbbVie$810
- Pfizer$510
- Merck$433
- Bayer$352
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,836100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 104 | $1,391 |
| AstraZeneca | 42 | $930 |
| AbbVie(2 entities) | 42 | $810 |
| Pfizer | 39 | $510 |
| Merck | 37 | $433 |
| Bayer | 21 | $352 |
| Boehringer Ingelheim | 22 | $319 |
| Novartis | 21 | $318 |
| Lilly USA, LLC | 20 | $220 |
| Amarin Pharma, Inc. | 13 | $201 |
| Kowa Pharmaceuticals America, Inc. | 7 | $169 |
| Amgen | 10 | $137 |
| Sanofi-aventis U.S. LLC | 10 | $137 |
| Exact Sciences | 7 | $115 |
| Johnson & Johnson | 7 | $96 |
| GSK | 7 | $94 |
| Daiichi Sankyo Inc. | 5 | $83 |
| Sunovion Pharmaceuticals Inc. | 4 | $66 |
| Abbott | 3 | $60 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Mylan Specialty L.p. | 3 | $38 |
| Corium, LLC | 1 | $34 |
| Exeltis, USA Inc. | 2 | $31 |
| Dexcom, Inc. | 2 | $31 |
| Strongbridge US Inc. | 2 | $26 |
| Organon | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Bioventus LLC | 1 | $12 |
How this compares
$6,849 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $156,228 |
| EliquisApixaban | 136 | $134,778 |
| JardianceEmpagliflozin | 117 | $109,573 |
| XareltoRivaroxaban | 46 | $44,505 |
| FarxigaDapagliflozin Propanediol | 38 | $34,047 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $25,990 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $25,341 |
| TrulicityDulaglutide | 18 | $20,243 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $20,097 |
| JanuviaSitagliptin Phosphate | 14 | $16,233 |
| Spiriva RespimatTiotropium Bromide | 15 | $15,010 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $14,109 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $13,912 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,319 |
| Xtampza ErOxycodone Myristate | 12 | $9,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,391 | $156,228136 claims |
| PfizerEliquis | $510 | $134,778136 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $319 | $124,583132 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $930 | $62,43390 claims |
| Johnson & JohnsonXarelto | $96 | $44,50546 claims |
| MerckJanumet, Januvia | $433 | $36,33034 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $94 | $25,55242 claims |
| Lilly USA, LLCTrulicity | $220 | $20,24318 claims |
| NovartisEntresto | $318 | $9,61714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Wauseon
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.